Mesoblast (MESO) Soars 208% YTD on Positive Regulatory...

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Nice to see sensational headlines at Yahoo Finance. Does anyone know much about the Incyte drug?

We note that Incyte Corporation’s INCY lead drug, Jakafi, is approved for the treatment of SR-aGvHD in adult and pediatric patients aged 12 years or older in the United States. Jakafi is a first-in-class JAK1/JAK2 inhibitor.INCY has a collaboration agreement with the Swiss pharma giant Novartis NVS for Jakafi. Notably, Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi outside the country.Incyte’s Jakafi was initially approved in the United States for the treatment of patients with polycythemia vera (PV), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF and post-essential thrombocythemia MF.

GLTALTH